A deep dive into 3 clinical cases of patients with myelodysplastic syndromes (MDS) is highlighting the heterogeneity of the clonal disorder while offering insight into the possibility of a ...

During a live event, Praneeth Baratam, MBBS, discussed the molecular factors that affect staging of lower-risk myelodysplastic syndromes.

Racial disparities are known to occur with many diseases, including numerous cancers, with Black individuals having lower survival rates than other racial/ethnic groups. However, there have not been ...

The prognostic impact of monocytosis in patients with myelodysplastic syndromes (MDS) is not well-studied and not been clearly defined. Patients with MDS and monocytosis had a shorter overall survival ...

Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 ...

BERKELEY HEIGHTS, N.J., Dec. 4, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel") announced today 1-year survival data from a Phase 2 randomized trial ...

“We saw really quite remarkable outcomes in a very high-risk MDS population, not only in response rates, but also in blood count improvement, long duration of response and improved overall survival,” ...

Characteristics including Ogata score and phenotypic aberrancies may correlate with mutational patterns that are predictive of treatment response in patients with myelodysplastic syndrome. This ...

Q: I hope you can answer some questions about myelodysplastic syndrome. What does it do to your body? Is there a known cause or cure? What is the prognosis? A: The myelodysplastic syndromes are a ...